Boehringer Ingelheim Launches Observational Study on Management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate mesylate)
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - March 22, 2016 Category: Research Source Type: news
Boehringer Ingelheim launches RE-COVERY DVT/PE™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate)
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 22, 2016 Category: Research Source Type: news
FDA Drug Safety Communication: Special storage and handling requirements must be followed for Pradaxa (dabigatran etexilate mesylate) capsules
[03-29-2011] The U.S. Food and Drug Administration (FDA) is alerting the public to important storage and handling requirements for Pradaxa (dabigatran etexilate mesylate) capsules. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 11, 2016 Category: Drugs & Pharmacology Source Type: news
Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate), Now Stocked in More Than 2,200 Hospitals
• New PRAXBIND.com tool enables physicians and patients to quickly locate local institutions where PRAXBIND is available (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - March 7, 2016 Category: Research Source Type: news
New drug reverses the effects of blood thinner in patients with brain hemorrhage
A new treatment can quickly and completely reverse the effects of the blood thinner dabigatran (Pradaxa) in patients suffering a brain bleed. The treatment, idarucizumab (Praxbind), is the first medication on the market designed to neutralize the blood thinner dabigatran. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 19, 2016 Category: Science Source Type: news
'Real-World' Study Offers New View of Pradaxa Bleeding Risk
(MedPage Today) -- Are RE-LY results reliable on dabigatran safety? (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 1, 2016 Category: Cardiology Source Type: news
Comunicado de la FDA sobre la seguridad de los medicamentos: Actualización sobre el riesgo de eventos severos de hemorragia con el anticoagulante Pradaxa (dabigatrán etexilato mesilato)
[5 de noviembre del 2012. La Administración de Alimentos y Medicamentos de Estados Unidos (FDA pos sus siglas en inglés) ha evaluado nueva información sobre hemorragias severas con el uso de los anticoagulantes dabigatrán (Pradaxa) y warfarina (Coumadin, Jantoven y medicamentos genéricos). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2016 Category: Drugs & Pharmacology Source Type: news
dabigatran (Pradaxa)
Title: dabigatran (Pradaxa)Category: MedicationsCreated: 1/11/2016 12:00:00 AMLast Editorial Review: 1/11/2016 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - January 11, 2016 Category: Drugs & Pharmacology Source Type: news
dabigatran (Pradaxa)
Title: dabigatran (Pradaxa)Category: MedicationsCreated: 1/11/2016 12:00:00 AMLast Editorial Review: 1/11/2016 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - January 11, 2016 Category: Cardiology Source Type: news
Reversing the effects of the new anti-clotting drugs
The oral anticoagulant warfarin (Coumadin) became available for prescription in 1954. This anti-clotting drug commanded national attention when President Dwight Eisenhower received the drug as part of his treatment following a heart attack. No other oral anticoagulant was successfully developed and marketed in the United States until 2010.
Warfarin is a dangerous drug. Along with insulin, it is responsible for the most emergency hospitalizations due to adverse drug reactions. Whereas insulin causes low blood sugar, warfarin is notorious for the complication of major bleeding. Warfarin is plagued by hundreds of drug-drug an...
Source: New Harvard Health Information - December 9, 2015 Category: Consumer Health News Authors: Samuel Z. Goldhaber, MD Tags: Drugs and Supplements Health Heart Health Hypertension and Stroke anti-clotting coumadin deep-vein-thrombosis DVT Source Type: news
Boehringer's Praxbind gets European approval for specific reversal of Pradaxa
Boehringer Ingelheim has received approval from the European Commission for Praxbind (idarucizumab), a treatment designed to quickly reverse the anticoagulant effects of Pradaxa (dabigatran etexilate) in cases of emergency surgery or in situations of… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - November 27, 2015 Category: Pharmaceuticals Source Type: news
Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)
• Idarucizumab is the first specific reversal agent for a NOAC to receive European approval1• idarucizumab immediately reverses the anticoagulant effect of dabigatran2-4 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 25, 2015 Category: Research Source Type: news
FDA OKs Pradaxa for Thromboprophylaxis After Hip SurgeryFDA OKs Pradaxa for Thromboprophylaxis After Hip Surgery
The FDA has approved dabigatran etexilate mesylate for prophylaxis of deep-vein thrombosis and pulmonary embolism after hip replacement surgery. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 24, 2015 Category: Consumer Health News Tags: Orthopaedics News Alert Source Type: news
FDA OKs Pradaxa for DVT, PE Prevention After Hip Surgery
(MedPage Today) -- Adds to NOAC pioneer's previous indications (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 24, 2015 Category: Cardiology Source Type: news
Boehringer Ingelheim Presents New idarucizumab (Praxbind®) Analyses on Reintroduction of Antithrombotic Therapy after Reversal of Dabigatran
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 9, 2015 Category: Research Source Type: news
